Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Anti-Müllerian Hormone in Breast Cancer Clinical Practice

NCT07896772 is registered in ClinicalTrials.gov with Masaryk Memorial Cancer Institute as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07896772 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Anti-Müllerian Hormone in Breast Cancer Clinical Practice
Lead sponsor
Masaryk Memorial Cancer Institute
Phase
Observational
Overall status
Recruiting
Start date
November 20, 2025
Completion date
December 31, 2027
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer

Arms

As registered; 2 arms.

  • Breast Cancer Patients

    Women aged 20-55 years with breast cancer at different stages of disease and treatment, including newly diagnosed treatment-naive patients, patients who have completed chemotherapy, patients receiving endocrine therapy without prior chemotherapy, and patients undergoing follow-up after treatment.

  • Healthy Controls

    Healthy women aged 20-55 years without a history of breast cancer.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Serum Anti-Müllerian Hormone (AMH) Levels Baseline (At the time of blood sampling)

    Serum AMH concentrations will be measured in women with breast cancer at different stages of treatment and in healthy female controls. The distribution of AMH levels will be described in both study populations.

Lead sponsor's other trials

Masaryk Memorial Cancer Institute, most recent start first.

Similar trials

Same condition (Breast Neoplasms) and phase, most recent start first.